Biofrontera Inc (BFRI)

Currency in USD
0.7001
-0.2258(-24.39%)
Closed·
0.7300+0.0299(+4.27%)
·

BFRI Earnings

Latest Release
Nov 13, 2026
EPS / Forecast
-0,42 / -0,15
Revenue / Forecast
9,07M / 9M
EPS Revisions
Last 90 days
Release Date
Period End
EPS
/Forecast
Revenue
/Forecast
EPS Surprise %
Revenue Surprise %
Reaction
2026/12--/0,310--/15,80M----Free Sign Up
2026/09-0,420/-0,1459,07M/9,00M-189,66%+0,78%Free Sign Up
2026/06-0,050/-0,14012,00M/10,50M+64,29%+14,29%Free Sign Up
2026/03-0,410/-0,06010,08M/---583,33%--Free Sign Up
2025/120,480/0,41017,10M/--+17,07%--Free Sign Up
2025/09-0,620/-0,5706,99M/---8,77%--Free Sign Up
2025/06-0,570/-0,5709,03M/--0%--Free Sign Up
2025/03-0,470/-0,1908,59M/---147,37%--Free Sign Up
2024/12-0,190/-0,20012,56M/14,33M+5%-12,35%Free Sign Up
2024/09-0,980/-1,029,01M/9,71M+3,92%-7,21%Free Sign Up

All numbers in USD

Biofrontera Inc Earnings Call Summary for Q3/2026

  • Q3 revenue rose 30% YoY to $9.1M driven by Ameluz volume growth and pricing, but EPS loss of $0.42 missed estimates by 190%.
  • Gross margin improved to 74.4% from 70.7%; FDA approved Ameluz for superficial basal cell carcinoma, creating second U.S. indication.
  • Stock fell 6% to $0.87 as company warned of substantial going-concern doubt with only $3.2M cash and Nasdaq equity deficiency.
  • Q4 expected to be strongest quarter with 80% gross margin; full sBCC commercial launch planned for Q1 2027 after FDA marketing review.
  • Company pursuing $1M milestone payment in Dec 2026 and working credit line; lamp remediation to complete by Q2 2027.
Last Updated: 2026/11/13, 17:38
Read Full Transcript

FAQ

What Is Biofrontera's Earnings Per Share (TTM)?

The Biofrontera EPS (TTM) is -0,48.

When Is The Next Biofrontera Earnings Date?

Biofrontera will release its next earnings report on Mar 19, 2027.

What Is Biofrontera’s Revenue Forecasts For Upcoming Quarters?

Biofrontera’s revenue forecast is 15.80M.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.